Yt90 Zevalin [ibritumomab-tiuxetan-Y-90] and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma.

Trial Profile

Yt90 Zevalin [ibritumomab-tiuxetan-Y-90] and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 04 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Planned end date changed from 1 Sep 2009 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top